ロード中...
Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease
BACKGROUND: Respiratory syncytial virus (RSV) is a viral pathogen that causes annual epidemics of lower respiratory tract infection with substantial morbidity and mortality in young children, especially those with congenital heart disease (CHD). Palivizumab is the only immunoprophylaxis therapy appr...
保存先:
| 出版年: | Ann Saudi Med |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
King Faisal Specialist Hospital and Research Centre
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7868616/ https://ncbi.nlm.nih.gov/pubmed/33550912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5144/0256-4947.2021.31 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|